Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06965569 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Phase 1 Study of ALA-3000
A Phase 1 study of Treatment-Resistant Depression, sponsored by Alar Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 4
- Study locations
NCT06965569 is a Phase 1 study of Treatment-Resistant Depression that has completed, run by Alar Pharmaceuticals. The registered enrollment target is 37 participants, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06965569, a Phase 1 study of Treatment-Resistant Depression, has completed, sponsored by Alar Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, multiple-dose study of ALA-3000 designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in subjects with treatment-resistant depression (TRD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALA-3000
- DRUG escitalopram, sertraline, duloxetine or venlafaxine XR
Study Locations (4)
Arkansas
- Pillar Clinical Research - Little Rock
Missouri
- Arch Clinical Trials - St Louis
New Jersey
- Clinilabs Drug Development Corporation - Eatontown
Ohio
- Neuro-Behavioral Clinical Research, Inc - North Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06965569
The ClinicalTrials.gov registry entry for NCT06965569 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (90% lower). The listed sponsor is Alar Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06965569 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arkansas, Missouri, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06965569 about?
NCT06965569 is a clinical study titled "Multiple Ascending Dose Phase 1 Study of ALA-3000". This is a randomized, double-blind, placebo-controlled, multiple-dose study of ALA-3000 designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in subjects with treatment-resistant depression (TRD).
What is the current status of trial NCT06965569?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2025-04-21. Estimated completion is 2025-12-30.
What conditions does trial NCT06965569 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression.
What interventions are being tested in trial NCT06965569?
The interventions under investigation include: Placebo (DRUG), ALA-3000 (DRUG), escitalopram, sertraline, duloxetine or venlafaxine XR (DRUG).
Who is sponsoring clinical trial NCT06965569?
This trial is sponsored by Alar Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06965569 being conducted?
This trial has 4 study locations across Arkansas, Missouri, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DBS for Depression
RECRUITING · Phase 1
-
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
COMPLETED · Phase 1
-
Home-administered tDCS for Treatment of Depression
COMPLETED · Phase 1
-
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
RECRUITING · NA
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.